BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mologen AG (MOLGF.PK) And MEBO: Joining Forces To Treat Cancer


10/19/2005 5:11:04 PM

MOLOGEN AG and MEBO International Group, a Chinese pharmaceutical corporation, signed a cooperation agreement. The agreement was signed by Professor Xu, president of MEBO and by MOLOGEN CEO Professor Wittig during a further business trip to Beijing and Guanzhou. By combining their respective technologies MEBO and MOLOGEN will jointly develop innovative combination treatment against cancer (CoCaT). The efficacy of combined cancer treatment will be evaluated through a clinical try in China. Mologen will contribute their 4-fold gene-modified and immunomodulated tumor cells. MEBO will provide pharmaceutically processed plant (herbal extracts), which induced the differentiation of tumor cells and inhibit metastases formation. CoCaT, for the very first time, combines "western" DNA and cell technology with "far-eastern" therapeutic approaches, having their origins in traditional Chinese medicines. Scientists and Business Developers of both companies hope that CoCaT will add to the therapeutic success in clinical trials, in comparison to either therapy supplied separately. MEBO and Mologen will jointly file for patents, if the cooperation deals new intellectual property. The partnership is intended to complement and benefit both partners in their scientific and business progress.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES